(Q36802592)

English

Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease

scientific article published on May 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

atherosclerosis

1 reference

based on heuristic

inferred from title

author name string

Marc Husmann

1

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Matthias Barton

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

language of work or name

0 references

publication date

1 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

563-567

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

A prospective study of the incidence of deep-vein thrombosis within a defined urban population

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice g

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Bivalirudin for patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Antithrombotic treatment for peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.563

21 January 2018

Identifiers

10.1517/13543784.16.5.563

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

release_yhyaovzczbff5iwyfweqp5yovq

1 reference

https://api.fatcat.wiki/v0/release/yhyaovzczbff5iwyfweqp5yovq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36802592&oldid=1837865038"